[1] Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study[J]. BMJ, 2020, 369.doi:10.1136/bmj.m997. [2] Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes[J]. Cell, 2001, 104: 517-529. [3] Gómez-Valadés AG, Méndez-Lucas A, Vidal-Alabró A, et al. Pck1 gene silencing in the liver improves glycemia control, insulin sensitivity, and dyslipidemia in db/db mice[J]. Diabetes, 2008, 57: 2199-2210. [4] Ling P, Lu TJ, Yuan CJ, et al. Biosignaling of mammalian Ste20-related kinases[J]. Cell Signal, 2008, 20: 1237-1247. [5] Avruch J, Zhou D, Fitamant J, et al. Protein kinases of the Hippo pathway: regulation and substrates[J]. Semin Cell Dev Biol, 2012, 23: 770-784. [6] Song H, Mak KK, Topol L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression[J]. Proc Natl Acad Sci U S A, 2010, 107: 1431-1436. [7] Geng C, Zhang Y, GAO Y, et al. Mst1 regulates hepatic lipid metabolism by inhibiting Sirt1 ubiquitination in mice[J]. Biochem Biophys Res Commun, 2016, 471: 444-449. [8] Matsumoto M, Ogawa W, Teshigawara K, et al. Role of the insulin receptor substrate 1 and phosphatidylinositol 3-kinase signaling pathway in insulin-induced expression of sterol regulatory element binding protein 1c and glucokinase genes in rat hepatocytes[J]. Diabetes, 2002, 51: 1672-1680. [9] Chung ST, Hsia DS, Chacko SK, et al. Increased gluconeogenesis in youth with newly diagnosed type 2 diabetes[J]. Diabetologia, 2015, 58: 596-603. [10] Ardestani A, Paroni F, Azizi Z, et al. MST1 is a key regulator of beta cell apoptosis and dysfunction in diabetes[J]. Nat Med, 2014, 20: 385-397. [11] 韩向晖, 季光. 肝脏糖异生的分子机制研究进展[J]. 世界华人消化杂志,2008,32: 3659-3665. [12] Unterman TG. Regulation of hepatic glucose metabolism by FoxO proteins, an integrated approach[J]. Curr Top Dev Biol, 2018, 127:119-147. |